SLRC

Business Context and Reporting Period

Company: SLR Investment Corp. (SLRC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended March 31, 2022
Business Overview: SLRC is a closed-end, externally managed, non-diversified business development company (BDC) regulated under the Investment Company Act of 1940. It invests primarily in leveraged middle-market companies via senior secured loans, financing leases, and equity securities. The company also operates subsidiaries including SLR Credit Solutions, SLR Equipment Finance, and Kingsbridge Holdings, LLC.

Key Financial Metrics

Material Changes vs. Prior Period

• Performance Decline: Net increase in net assets from operations dropped significantly from $21.5 million in Q1 2021 to $1.5 million in Q1 2022. This was primarily driven by a net unrealized loss of $12.0 million in Q1 2022, compared to a gain of $6.4 million in the prior year.
• Unrealized Loss Drivers: The unrealized loss was largely due to depreciation in the value of investments in PhyMed Management LLC and Rug Doctor LLC, partially offset by appreciation in KBH Topco, LLC, SOC Telemed, Inc., and Cerapedics, Inc.
• Expense Reduction: Total expenses decreased to $19.5 million from $20.4 million year-over-year. This reduction was primarily due to the elimination of performance-based incentive fees ($0 in Q1 2022 vs. $3.9 million in Q1 2021), partially offset by higher general and administrative expenses related to the pending merger.
• Portfolio Activity: The company invested approximately $67.5 million in 14 portfolio companies and sold/repaid approximately $101.0 million during the quarter.
• Liquidity Position: Cash and cash equivalents increased significantly to $588.9 million from $322.9 million at the end of 2021, reflecting a strategic buildup of temporary assets.

Guidance, Outlook, and Material Events

• Merger with SLR Senior Investment Corp. (SUNS): The company completed the merger with SUNS on April 1, 2022. The transaction was accounted for as an asset acquisition. The company issued approximately 12.5 million shares to former SUNS stockholders.
• Management Fee Reduction: In connection with the merger, the Investment Adviser agreed to a permanent 25 basis point reduction in the annual base management fee rate, lowering it to 1.50% on gross assets up to 200% of net assets.
• Stock Repurchase Program: On May 3, 2022, the Board authorized a program to repurchase up to $50 million of outstanding common stock.
• Distributions: The Board declared monthly distributions of $0.136667 per share for May and June 2022.
• Legal Proceedings: Several stockholder complaints regarding the merger (collectively the "Merger Complaints") were filed in early 2022. As of April 2022, these complaints were voluntarily dismissed or dismissed as to named plaintiffs.
• Risk Factors: The company highlighted risks related to the integration of the SUNS portfolio, the potential inability to realize anticipated synergies, and the economic impact of the Russian invasion of Ukraine.

Investor Verification Checklist

• Merger Integration: Verify the progress of integrating SUNS's portfolio and operations and the realization of projected cost savings.
• Unrealized Losses: Review the specific valuation methodologies and credit status of portfolio companies contributing to the $12.0 million unrealized loss (e.g., PhyMed, Rug Doctor).
• Debt Maturities: Monitor upcoming debt maturities, specifically the $150 million 2022 Unsecured Notes due May 2022 and the $21 million 2022 Tranche C Notes due December 2022.
• Asset Coverage: Confirm continued compliance with the 150% asset coverage ratio required under the Investment Company Act of 1940, especially given the increased leverage from the merger.
• Stock Repurchase Execution: Track the execution of the newly authorized $50 million stock repurchase program and its impact on share count and NAV.